Nicolas Frances
Basel, BS, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications
Patient-Centric First-in-Human Dose Selection: An Ex Vivo Minimal Anticipated Biological Effect Level Approach for T-Cell Engagers in Multiple Myeloma.
Journal: Clinical pharmacology and therapeutics
Published: March 07, 2026
Leveraging in vitro Tumor Cell Killing and Cytokine Release to Predict Cytokine Release Syndrome Associated with CD3 T-cell Bispecifics in Oncology: a Retrospective Analysis.
Journal: The AAPS journal
Published: July 22, 2025
A Model-Based Approach to Evaluate Anti-Drug Antibody Impact on Drug Exposure With Biologics: A Case Example With the CD3 T-Cell Bispecific Cibisatamab.
Journal: CPT: pharmacometrics & systems pharmacology
Published: October 31, 2024
Combining mathematical modeling, in vitro data and clinical target expression to support bispecific antibody binding affinity selection: a case example with FAP-4-1BBL.
Journal: Frontiers in pharmacology
Published: July 29, 2024
Mechanistic PKPD modeling to describe cytokine release associated with CD3 T-cell engager therapies.
Mechanistic PKPD modeling to describe cytokine release associated with CD3 T-cell engager therapies.
Journal: Frontiers in immunology
Published: July 12, 2024
A model-based approach leveraging in vitro data to support dose selection from the outset: A framework for bispecific antibodies in immuno-oncology.
Journal: CPT: pharmacometrics & systems pharmacology
Published: July 10, 2023
Correction: Preclinical In Vivo Data Integrated in a Modeling Network Informs a Refined Clinical Strategy for a CD3 T‑Cell Bispecific in Combination with Anti‑PD‑L1.
Journal: The AAPS journal
Published: March 31, 2023
A prognostic baseline blood biomarker and tumor growth kinetics integrated model in paclitaxel/platinum treated advanced non-small cell lung cancer patients.
Journal: CPT: pharmacometrics & systems pharmacology
Published: November 13, 2022
Preclinical InVivo Data Integrated in a Modeling Network Informs a Refined Clinical Strategy for a CD3 T-Cell Bispecific in Combination with Anti-PD-L1.
Journal: The AAPS journal
Published: June 23, 2022
Novel in Vivo and in Vitro Pharmacokinetic/Pharmacodynamic-Based Human Starting Dose Selection for Glofitamab.
Journal: Journal of pharmaceutical sciences
Published: August 20, 2021
Preclinical Characterization of a Next-Generation Brain Permeable, Paradox Breaker BRAF Inhibitor.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: July 29, 2021
Predicting Tumor Killing and T-Cell Activation by T-Cell Bispecific Antibodies as a Function of Target Expression: Combining In Vitro Experiments with Systems Modeling.
Journal: Molecular cancer therapeutics
Published: April 24, 2020
Last Updated: 09/26/2026